Hamlet BioPharma says oral BAMLET cuts weight gain, blood glucose in obesity, diabetes models

Hamlet BioPharma highlighted new preclinical data on oral BAMLET, published Sept. 19, 2026 in Scientific Reports. Study found reduced weight gain, lower blood glucose, less adipose tissue growth in obesity and diabetes models; no effect in healthy mice. Intestinal barrier function improved within three days in a chronic diabetes model, supporting an intestine-focused mechanism. Researchers reported lower GLUT2 levels, inhibited glucose uptake, altered adiponectin and leptin signaling, pointing to multi-pathway metabolic effects. Commercial strategy targets nutrition products first, while